Status:

UNKNOWN

Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

Lead Sponsor:

Ewha Womans University

Collaborating Sponsors:

The Catholic University of Korea

Kyung Hee University Hospital at Gangdong

Conditions:

Glomerulonephritis, Immunoglobulin A (IgA)

Eligibility:

All Genders

19+ years

Phase:

PHASE3

Brief Summary

Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is progressive, particularly when patients have a significant proteinuria (proteinuria \>1g/g creatinine), imp...

Eligibility Criteria

Inclusion

  • Biopsy-proven IgAN: dominant or co-dominant deposits of mesangial IgA in immunofluorescence stain
  • Age \>= 19 years
  • Random urine protein-to-creatinine ratio 0.3 g/g creatinine to 1.0 g/g creatinine at visit 1
  • Estimated glomerular filtration rate \>= 60 mL/min/1.73m2 at visit 1
  • People who voluntarily agreed to participate
  • People who are compliant

Exclusion

  • Prevalent Hypertension: systolic blood pressure \>=140 mmHg and \>=90 mmHg, previous physician diagnosis of hypertension, or taking anti-hypertensive drugs
  • Prevalent Diabetes: fasting glucose \>= 126 mg/dL, HbA1c \>= 6.5%, taking insulin or anti-diabetic drugs, or previous physician diagnosis of diabetes
  • Previous immunosuppressive drugs use to treat IgAN
  • Secondary IgAN
  • Renin-angiotensin-aldosterone inhibitors (RASI) dependent patients (congestive heart failure, ischemic heart disease, and others)
  • hypersensitivity to RASI
  • Other chronic diseases: malignancy within 5 years, significant liver and gastrointestinal disease and other autoimmune disease
  • Pregnancy
  • symptomatic orthostatic hypotension
  • People who already participated in other interventional studies or taking interventional drugs within 3 month of screening visit
  • Inappropriate people ascertained by investigator

Key Trial Info

Start Date :

January 30 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2021

Estimated Enrollment :

174 Patients enrolled

Trial Details

Trial ID

NCT03357653

Start Date

January 30 2018

End Date

December 31 2021

Last Update

November 30 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 | DecenTrialz